Here, we observed somatic DNMT3A variants in four (11%) out of 37 RUNX1-FPD AMLs, one RUNX1-FPD myeloproliferative neoplasm, and one RUNX1-FPD thrombocytopenia patient. This evidence concerns the gene RUNX1 and myeloproliferative disorder.